Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Carcinoma × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 7 Recurrence 5 Glioblastoma 4 Leukemia, Myeloid, Acute 3 Colorectal Neoplasms 3 Neoplasms, Plasma Cell 2 Melanoma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioma 2 Carcinoma, Squamous Cell 2 Brain Neoplasms 2 Astrocytoma 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Thymoma 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Richter's Transformation 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1

Interventions

Carboplatin 21 Cisplatin 14 pembrolizumab 12 Paclitaxel 12 Gemcitabine 12 Pemetrexed 9 130-nm albumin-bound paclitaxel 9 Everolimus 8 Cetuximab 6 durvalumab 5 Fluorouracil 5 Docetaxel 5 Cyclophosphamide 5 Axitinib 5 Albumin-Bound Paclitaxel 5 osimertinib 4 Sunitinib 4 Radiotherapy 4 Nivolumab 4 Ipilimumab 4 Erlotinib Hydrochloride 4 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 Radiation 3 Octreotide 3 Irinotecan 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 vosaroxin 2 pralsetinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02213133 2023-01-26

STARRS

Karyopharm Therapeutics Inc

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡